Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{149343,
        author = {Yewange Sangmeshwar and Deshpande Renuka and Nikhil Waghmare and Vidyasagar Gali and Shyamlila B. Bavage and Nandkishor B. Bavage},
        title = {Chloroquine and hydroxychloroquine as potential therapies against COVID-19},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {6},
        number = {12},
        pages = {15-19},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=149343},
        abstract = {The desperate search to find effective treatments for coronavirus disease 2019 (COVID-19), 2 generic drugs, used largely by rheumatologists and dermatologists to treat immune-mediated diseases, have entered the spotlight. The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) have demonstrated antiviral activity against severe acute respiratory syndrome–coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly controlled or uncontrolled clinical studies (1–3). Normally, such research would be deemed hypothesis-generating at best.  Here, we try to provide guidance regarding clinical decision making both for patients with COVID-19 and those with immune-mediated conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and strategies to mitigate further harm to these patients.},
        keywords = {chloroquine clinical research clinical trials corona virus in COVID-19 disease & medicine hydroxychloroquine malaria nut shell SARS-CoV-2},
        month = {},
        }